39 results about "Molecular virology" patented technology

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of novel coronaviruses. Specifically, the present inventionrelates to an anti-novel coronavirus monoclonal antibody, and a composition (e.g., a diagnostic agent and a therapeutic agent) comprising the antibody. Furthermore, the invention also relates to an application of the antibody. The antibody provided by the invention can be applied to diagnosis, prevention and / or treatment of infection of the novel coronavirus and / or diseases (e.g., novel coronavirus pneumonia) caused by the infection.

The invention provides a single-chain antibody for resisting S1 protein on the surface of a new coronavirus SARS-CoV-2, and relates to the technical fields of cellular immunology and molecular virology. The monoclonal antibody comprises heavy-chain variable regions of an scFv-22 sequence and with amino acid sequences shown as SEQ ID NO. 1-3 and light-chain variable regions of the scFv-22 sequence and with amino acid sequences shown as SEQ ID NO. 5-7, or heavy-chain variable regions of a scFv-24 sequence and with amino acid sequences shown as SEQ ID NO. 9-11 and light-chain variable regions of tje scFv-24 sequence and with amino acid sequences shown as SEQ ID NO. 13-16. The single-chain antibody disclosed by the invention can specifically bind to S1 protein of the novel coronavirus SARS-CoV-2, has neutralizing activity on the novel coronavirus, effectively inhibits infection of the novel coronavirus on target cells, and can be used for developing drugs for preventing or treating novel coronavirus infection.

The invention relates to the technical field of immunology and molecular virology, and particularly discloses a monoclonal antibody of novel coronavirus and a mutant thereof and application of the monoclonal antibody. Complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or an antigen binding fragment thereof respectively have amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment thereof respectively have amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The monoclonal antibody disclosed by the invention can be combined with the S protein RBD of the novel coronavirus and various mutant strains thereof with high affinity, is strong in neutralizing activity, and has ideal clinical application value for preventing and treating infection of the novel coronavirus and various mutant strains thereof.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of SARS-Cov-2. In particular, the present invention provides monoclonal antibodies that can recognize SARS-Cov-2 mutants, as well as compositions (e.g., diagnostic agents and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibody of the invention can be used for diagnosis, prevention and / or treatment of SARS-Cov-2 infection and / or diseases caused by the infection (e.g., COVID-19).

The invention relates to the field of molecular virology and immunology, and particularly, relates to a gene sequence for encoding a human papillomavirus 31 type L1 protein and with a termination codon of TAG, and an encoded protein and a preparation method thereof, and virus-like particles containing the encoded protein; the protein and the virus-like particles can be used for preventing HPV (especially HPV31) infection and diseases such as cervical cancer and the like caused by the HPV (especially HPV31) infection. The invention also relates to an application of the protein and the virus-like particles in preparation of a pharmaceutical composition or a vaccine. The pharmaceutical composition or the vaccine is used for preventing the HPV (especially HPV31) infection and the diseases such as cervical cancer and the like caused by the HPV (especially HPV31) infection.

The invention relates to the technical field of immunology and molecular virology, and particularly discloses a novel coronavirus, a monoclonal antibody of a mutant of the novel coronavirus and application of the monoclonal antibody. According to the monoclonal antibody or an antigen binding fragment of the monoclonal antibody, CDR1 of a heavy chain variable region has an amino acid sequence shown as SEQ ID NO: 1, CDR2 has an amino acid sequence shown as SEQ ID NO: 2, and CDR3 has an amino acid sequence shown as SEQ ID NO: 3; and / or CDR1 of a light chain variable region has an amino acid sequence shown as SEQ ID NO: 4, CDR2 has an amino acid sequence shown as SEQ ID NO: 5, and CDR3 has an amino acid sequence shown as SEQ ID NO: 6. The monoclonal antibody can be combined with the novel coronavirus and various mutant strain S protein RBD of the novel coronavirus with high affinity, is high in neutralizing activity and has ideal clinical application value for preventing and treating infection of the novel coronavirus and various mutant strains of the novel coronavirus.

The invention provides a single chain antibody capable of resisting S2 protein on the surface of novel coronavirus SARS-CoV-2, and relates to the technical field of cellular immunology and molecular virology. The monoclonal antibody includes a variable region of a heavy chain of an scFv-27 sequence including amino acid sequences shown as SEQIDNO. 1-3, and a variable region of a light chain including amino acid sequences shown as SEQIDNO. 5-7, or include a variable region of a heavy chain of an scFv-32 including the amino acid sequences shown as SEQIDNO. 9-11, and a variable region of a light chain including the amino acid sequences shown as SEQIDNO. 13-16. The single chain antibody can be specifically combined with the S2 protein of the novel coronavirus SARS-CoV-2; and the single chain antibody has neutralization activity, can effectively inhibit infection of the novel coronavirus to target cells, and can be used for developing drugs for preventing or treating the infection of the novel coronavirus.

The invention relates to a method for constructing infectious clone of an encephalomyocarditis virus. The method comprises the following steps: extracting the total RNA of the encephalomyocarditis virus; piecewise amplifying the full-length cDNA of the encephalomyocarditis virus by an RT-PCR method, and separately constructing sub-clones; and directionally cloning each fragment of the cDNA sequentially to a low copy plasmid carrier by a double-enzyme cutting method so as to obtain the infectious clone of the encephalomyocarditis virus. The method has small operation difficulty and strong controllability, and can obtain stable infectious clone of the encephalomyocarditis virus, thereby providing an effective tool for the molecular virology research of the encephalomyocarditis virus and the development of vaccines.

The invention relates to the fields of molecular virology and genetic engineering. In particular, the invention relates to an HIV (human immunodeficiency virus) envelope protein, a coding sequence thereof, and an HIV pseudovirus comprising the HIV envelope protein; the HIV pseudovirus can be used to detect ADCC (antibody-dependent cell-mediated cytotoxicity) activity of an anti-HIV antibody. The invention also relates to a kit for detecting the ADCC activity of the anti-HIV antibody. The invention further relates to a method for detecting the ADCC activity of the anti-HIV antibody by using the HIV pseudovirus, the method can achieve rapid, simple and high-throughput detection of the ADCC activity of the anti-HIV antibody, and thereby the method is of great significance for protection effect on analysis of vaccine immune response, and development and quality control of a new vaccine.

The invention belongs to the filed of animal molecular virology. The invention discloses a loop-mediated isothermal amplification reaction primer for detecting porcine parvovirus II (PPV II). According to a method, two pairs of primers consisting of outer primers F3 and B3 and inner primers FIP and BIP are designed according to a forepart conserved sequence of a porcine parvovirus II VP1 gene. The specific sequences of the two pairs of primers are shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4. A loop-mediated isothermal amplification method for detecting porcine parvovirus II (PPV II) is established according to the designed primer. No cross reaction occurs in porcine ordinary infectious disease viruses according to the detection method. The detection method has strong on-site practicability without requiring expensive instrument and equipment, high accuracy, strong specificity and high sensitivity.

The invention belongs to the field of molecular virology, and particularly relates to a binding site of interacting a major capsid protein L1 and a secondary capsid protein L2 of a human papilloma virus L1L2. The protein binding site and an area can serve as target sites for preventing HPV infection and diseases such as a cervical cancer caused HPV infection. The invention further relates to an HPV mutant type L1 protein. The invention further relates to a medicament composition and applications of the preparation medicament composition in treating and / preventing and / adjuvantly treating HPV infection and diseases such as a cervical cancer caused by HPV infection.

The invention relates to the virus detection technologies in the fields of molecular biology and molecular virology, and in particular relates to a reverse transcription fluorogenic quantitative PCR primer for rapidly identifying a high virulent Newcastle disease virus (NDV) strain and a method for identifying the high virulent NDV strain by adopting the PCR primer. The method comprises the following steps: extracting RNA of a to-be-identified virulent strain, carrying out RT-qPCR amplification, and identifying that the to-be-identified virus is the high virulent NDV strain when viral nucleic acid is successfully amplified; and identifying that the to-be-identified virus is not the high virulent NDV strain when the viral nucleic acid is not successfully amplified. According to the identification method, only once RT-qPCR amplification is needed, whether the to-be-identified virus is the high virulent NDV strain or not can be judged, and the detection method is simple, convenient and flexible, and is easy to operate; the detected minimum concentration of RNA is 1 copy / mu L, and the detection sensitivity is high; the design primer only can amplify the high virulent NDV strain, and can not amplify low virulent strains and other virulent strains, and therefore, the specificity is strong.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of hepatitis B virus. Specifically, the invention relates to a monoclonal antibody of the hepatitis B virus e antigen, and also relates to a detection reagent (especially a chemiluminescence method) of the hepatitis B virus e antigen.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of novel coronaviruses. In particular, the invention relates to a monoclonal antibody against novel coronaviruses, and a composition (e.g., diagnostic and therapeutic agents) comprising the antibody. In addition, the invention also relates to an application of the antibody. The antibody can be used for diagnosing, preventing and / or treating infection of the novel coronaviruses and / or diseases caused by the infection (e.g., novel coronavirus pneumonia).

The invention relates to the technical field of biology, in particular to recombinant baculoviruses which express grass carp reovirus spike protein VP65 and application. The recombinant baculovirusesare generated when recombinant plasmids of pFast-HTA-VP56 are built and converted into recombinant baculoviruses. According to the recombinant baculoviruses which express the grass carp reovirus spikeprotein VP56 and application, by building the pFast-HTA-VP56 plasmids and using a baculovirus expression system, the baculoviruses with his tag protein of soluble protein of the grass carp reovirus spike protein VP56 are recombined and expressed, by means of the baculoviruses, a large amount of expressed soluble VP56 protein in SF9 (insect cells) can be infected, and the baculoviruses are appliedto relative operation of molecular virology.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of novel coronaviruses. In particular, the invention relates to a monoclonal antibody against novel coronaviruses, and a composition (e.g., diagnostic and therapeutic agents) comprising the antibody. In addition, the invention also relates to an application of the antibody. The antibody can be used for diagnosing, preventing and / or treating infection of the novel coronaviruses and / or diseases caused by the infection (e.g., novel coronavirus pneumonia).

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of SARS-CoV-2. In particular, the present invention relates to monoclonal antibodies against SARS-CoV-2, as well as compositions (e.g., diagnostic agents and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibodies of the invention can be used for diagnosing, preventing and / or treating SARS-CoV-2 infection and / or diseases caused by the infection (e.g., COVID-19).

The invention relates to the technical field of biology, in particular to recombinant baculoviruses which express grass carp reovirus spike protein VP55 and application. The recombinant baculovirusesare generated when recombinant plasmids of pFast-HTA-VP55 are built and converted into recombinant baculoviruses. According to the recombinant baculoviruses which express the grass carp reovirus spikeprotein VP55 and application, by building the pFast-HTA-VP55 plasmids and using a baculovirus expression system, the baculoviruses with his tag protein of soluble protein of the grass carp reovirus spike protein VP55 are recombined and expressed, by means of the baculoviruses, a large amount of expressed soluble VP55 protein in SF9 (insect cells) can be infected, and the baculoviruses are appliedto relative operation of molecular virology.

The invention belongs to the field of molecular virology, and particularly relates to a binding site of interacting a major capsid protein L1 and a secondary capsid protein L2 of a human papilloma virus L1L2. The protein binding site and an area can serve as target sites for preventing HPV infection and diseases such as a cervical cancer caused HPV infection. The invention further relates to an HPV mutant type L1 protein. The invention further relates to a medicament composition and applications of the preparation medicament composition in treating and / preventing and / adjuvantly treating HPV infection and diseases such as a cervical cancer caused by HPV infection.

This invention discloses inhibitory peptides of HBV polymerase protein YMDD functional domain, and their application. This invention utilizes short peptides of HBV polymerase protein YMDD functional domain as the target, and screens peptides that can specifically bind the target by phage surface display technique. The screened three kinds of inhibitory peptides are Trp Try Thr Asn Asn Ser Thr, Gly Pro Phe Asn Asn Pro Pro, and Gly Trp Leu Pro Pro Pro Asp. Experiments show that the three kinds of inhibitory peptides have obvious inhibitive effect on DNA of HBV, thus provide new raw materials for anti-HBV drugs. Compared with the present nucleotide drugs that act on HBV DNA synthesis, the inhibitory peptides in this invention can inhibit the duplication of HBV. The inhibitory peptides are complementary with present lamivudine drugs, and are suitable for development of anti-HBV drugs and research of HBV molecular virology.

The present invention relates to the fields of immunology and molecular virology, in particular the diagnosis, prophylaxis and treatment of coronaviruses, such as SARS-CoV-2 and / or SARS-CoV-1. In particular, the present invention relates to monoclonal antibodies against coronavirus, as well as compositions (e.g., diagnostic and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibodies of the invention can be used for diagnosing, preventing and / or treating coronavirus infection and / or diseases caused by the infection.

The invention relates to the fields of immunology and molecular virology, and in particular, relates to the field of diagnosis, prevention and treatment of novel coronavirus. In particular, the invention relates to monoclonal antibodies against novel coronaviruses, as well as compositions (such as a diagnostic agent and a therapeutic agent) comprising the antibodies. In addition, the invention also relates to preparation, screening and application of the antibodies.

This invention discloses inhibitory peptides of HBV polymerase protein YMDD functional domain, and their application. This invention utilizes short peptides of HBV polymerase protein YMDD functional domain as the target, and screens peptides that can specifically bind the target by phage surface display technique. The screened three kinds of inhibitory peptides are Trp Try Thr Asn Asn Ser Thr, Gly Pro Phe Asn Asn Pro Pro, and Gly Trp Leu Pro Pro Pro Asp. Experiments show that the three kinds of inhibitory peptides have obvious inhibitive effect on DNA of HBV, thus provide new raw materials for anti-HBV drugs. Compared with the present nucleotide drugs that act on HBV DNA synthesis, the inhibitory peptides in this invention can inhibit the duplication of HBV. The inhibitory peptides are complementary with present lamivudine drugs, and are suitable for development of anti-HBV drugs and research of HBV molecular virology.

The inhibiting peptide of hepatitis B virus polymerase protein YMDD function zone and application belong to the field of molecular biology and biological chemistry of biological technology. Said invention uses short peptide of hepatitis B virus polymerase protein YMDD function zone as target position, and utilizes bacteriophage surface spreading technique to screen the peptide which can be combined with specificity of the described target position. The amino acid sequences of three inhibiting peptides screened by said invention respectively are Trp Try Thr Asn Asn Ser Thr; Gly Pro Phe Asn Asn Pro Pro; and Gly Trp Leu Pro Pro Pro Asp. The tests show that said three inhibiting peptides have obvious inhibiting action fro DNA of HBV.